OR WAIT null SECS
Almac is investing GBP16 million to expand its formulation and analytical development services and has successfully negotiated to operate in the Charnwood Campus in Loughborough, England.
The CDMO Almac Group announced that it is investing GBP16 million to expand its formulation and analytical development services in response to client demand.
Almac has successfully negotiated to operate in a significant proportion of the 70-acre Charnwood Campus in Loughborough, England, which is a science, technology and enterprise park. Almac will be using the formulation development and analytical testing facilities at the site, which will complement existing development and GMP services offered from its Craigavon NI headquarters.
The Charnwood facilities were originally designed and built by a global pharmaceutical company as part of its in-house formulation development, clinical manufacturing, and analytical testing capabilities.
Almac has now commenced recommissioning of the facilities and is investing GBP16 million in process and analytical technologies. Plans have been made to expand its non-potent and potent solid oral dose processing operations and it is estimated that the expansion will created approximately 180 new jobs during the next five years.
The start date to begin full operation has been set for the first quarter of 2017.